PubMed · 1991 · 22 citations · 14 references
MedicineNuclear MedicinePharmaceuticsEndocrine Nuclear MedicineOncologic Nuclear MedicineTherapeutic Nuclear MedicineNuclear Medicine ChemistryRadiopharmaceutical PreparationRadiopharmaceuticalsChemical LabellingDiagnostic RadiopharmaceuticalsMedullary Thyroid Carcinoma DiagnosisRadiochemical Purity AssessmentRadiochemical Purity SpecificationsRadiochemical Purity TestingRadiopharmaceutical ImagingRadiopharmaceutical Quality Assurance
A cold kit has been developed for the instant preparation of 99mTc-(V)-DMSA. The radiochemical purity of the radiopharmaceutical was determined by chromatography. A study of the effect of pH and stannous chloride concentrations on its labelling efficiency demonstrated that pH 8.5-9.0 and 0.2 mg stannous chloride for 1.1 mg DMSA provides the optimum formulation (98%). The addition of ascorbic acid stabilized the kit for up to 24 weeks under refrigerated temperatures. The radiopharmaceutical was found to concentrate in the bone and muscles in contrast to trivalent DMSA which accumulates in the liver and kidneys in normal mice. Studies in patients have shown its usefulness in the scintigraphy of thyroid medullary carcinoma and in the brain metastasis of breast carcinoma.
14
Determinants of tumor blood flow: a review.
R K Jain · PubMed · 1988 · 1.4K citations
Medicine, Cancer Biology, Oncology +17
Intratumor microvessel density as a prognostic factor in cancer.
Noel Weidner · PubMed · 1995 · 876 citations
Jerrold L. Boxerman, Kathleen M. Schmainda, Robert M. Weisskoff · PubMed · 2006 · 648 citations · Full text